Yixintang Pharmaceutical Group Co., Ltd. engages primarily in pharmaceutical retail chain operations and pharmaceutical distribution across China. The company offers traditional Chinese medicines, western medicines, medical equipment, birth control products, disinfection products, healthcare products, and medical devices through an extensive network of chain drugstores under brands including Hongxiang, Shanshang, Huipin, Bendian, and Hanzun; it also produces proprietary pharmaceuticals and provides wholesale distribution services. Founded in 2000 and headquartered in Kunming, Yunnan province, Yixintang operates predominantly in southwest China with expansions into South China, Northern China, Central China, and East China regions, employing over 36,000 people and serving urban and rural markets as a key player in the domestic healthcare supply chain. Recent developments include the completion of an acquisition of assets and inventories from 10 stores of Yiliang Yijun Pharmaceutical Co., Ltd. for CNY 8.40 million in February 2024; authorization and execution of multiple share buyback plans, such as one in February 2025 for up to CNY 150 million and another closed in November 2024; and funding injections to subsidiaries like Yixintang Pharmaceutical, Yixin Convenience Store Chain, Guizhou Hongxiang Yixintang, Sichuan Yixintang, Guangxi Hongxiang Yixintang, and Chongqing Hongxiang Yixintang totaling over CNY 300 million in 2024-2025 to support operational expansions.